ONC vs. VTRS: BeOne Medicines vs. Viatris Stock Comparison

Company Profile

BeOne Medicines (ONC) and Viatris (VTRS) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ONC is classified in Biotechnology while VTRS is classified in Pharmaceuticals.

Viatris (VTRS) trades as ordinary local shares, while BeOne Medicines (ONC) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Viatris (VTRS) reports a negative ROE of -4.21%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile BeOne Medicines (ONC) reports 18.40%, ranking against industry peers normally.

Viatris (VTRS) reports a negative net margin of -4.13%, usually indicating a net loss over the period. Meanwhile BeOne Medicines (ONC) reports 13.86%, ranking against industry peers normally.

BeOne Medicines (ONC) at 22.15% operates in the top operating margin quartile, ahead of Viatris (VTRS) at 13.85%, which runs around its industry’s norm.

Profitability Metrics

Growth

BeOne Medicines (ONC) at 40.23% is around its peer norm for revenue growth, while Viatris (VTRS) at -2.98% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Neither BeOne Medicines (ONC) nor Viatris (VTRS) reports a EPS growth value for this period, so a direct comparison isn't possible.

Growth Metrics

Financial Strength

BeOne Medicines (ONC) at 3.55 keeps current ratio within its industry’s typical mid-range, while Viatris (VTRS) at 1.55 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for VTRS.

BeOne Medicines (ONC) at 0.35 carries an industry-typical debt-to-equity mix, while Viatris (VTRS) at 0.99 uses more debt funding than most peers.

Financial Strength Metrics

Dividends

BeOne Medicines (ONC) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Viatris (VTRS) reports a yield of 2.53%, ranking against industry peers normally.

Viatris (VTRS) reports payout ratio above 100% at 960.00%, meaning dividends exceeded current-period earnings; BeOne Medicines (ONC) pays no dividend (payout 0.00%).

Dividend Metrics

Valuation

An earnings multiple is available for just one side: BeOne Medicines (ONC) trades at 52.17 times trailing earnings, ranked against its peers, while Viatris (VTRS) has no P/E ratio this period.

Viatris (VTRS) at 1.55 sits in the cheaper P/S ratio quartile while BeOne Medicines (ONC) at 7.04 prices around its industry’s middle — VTRS costs less per dollar of sales, though read it alongside growth and margins.

Viatris (VTRS) at 1.67 looks cheap against book in the lower P/B ratio quartile, while BeOne Medicines (ONC) at 7.98 carries a premium in the upper quartile — a clear price-to-book gap.

Valuation Metrics